The U.S. Food and Drug Administration has granted accelerated approval for aducanumab to treat Alzheimer’s disease.

Aducanumab is a first-of-its-kind treatment that has been approved for Alzheimer’s disease and represents the first new treatment approved for the condition since 2003. It is also the first treatment that targets the fundamental pathophysiology of the disease.

The drug was evaluated in three different studies involving 3,482 patients. The studies included double-blind, randomized, placebo-controlled dose-ranging trial among patients with Alzheimer’s disease. Patients given the drug reported significant dose-and time-dependent reduction of amyloid beta plaque. On the contrary, patients in the control group of the studies were found to have no reduction of amyloid beta plaque… (FDA, June 7, 2021)